분자진단 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 검사 장소별, 기술별, 용도별, 지역별, 부문별 예측(2026-2033년)

Molecular Diagnostics Market Summary

The global molecular diagnostics market size was estimated at USD 18.85 billion in 2025 and is projected to reach USD 25.59 billion by 2033, growing at a CAGR of 4.06% from 2026 to 2033. Key drivers of this growth include ongoing technological advancements, a steadily aging population, and rising demand for precise, efficient genetic testing solutions.

In addition, the increasing adoption of Point-of-Care (POC) testing driven by the need for convenient self-diagnostic tools and greater patient awareness of the benefits of rapid results is encouraging companies to innovate and introduce new testing products.

As demand for point-of-care testing (POCT) continues to grow, several emerging trends are reshaping the market and strengthening its role within molecular diagnostics. One major shift is the increasing specialization of clinical departments, prompting the development of tailored POCT solutions for diverse medical applications. This aligns with the broader movement toward healthcare decentralization, where advanced diagnostic technologies are becoming more accessible in smaller facilities. As a result, POCT systems are being designed with greater precision, speed, and cost-efficiency.

Market players are actively developing innovative POCT products to capitalize on new opportunities. For example, in November 2024, Texas launched a pilot program focused on self-collected HPV screening to expand access to cervical cancer testing in underserved regions. Conducted at Su Clinica Federally Qualified Health Center (FQHC) in collaboration with The University of Texas MD Anderson Cancer Center, the initiative aims to evaluate the real-world effectiveness of self-collection screening. Using the FDA-approved BD Onclarity HPV Assay, the program addresses geographic and socioeconomic barriers to cervical cancer detection and examines strategies to improve healthcare delivery. By demonstrating the practicality of self-collection methods in resource-limited environments, the program supports broader adoption of POCT solutions and reinforces trust among providers and policymakers.

Companies such as Sigma Aldrich and QIAGEN are leveraging advanced technologies like TMA and LAMP for tumor diagnostics, while next-generation sequencing (NGS) remains one of the fastest-growing segments due to its widespread use in genomic research. The introduction of new systems-such as Thermo Fisher's 5500x1 genetic analyzer and Illumina's NextSeq CN500-along with the rising use of multiplex and real-time PCR platforms (e.g., QIAGEN's EpiTect Methyl II PCR) continues to stimulate market expansion.

Through focused R&D and strategic collaborations, leading manufacturers are broadening their portfolios of qPCR and disease-specific diagnostic tests. Notable advancements in oncology and infectious disease testing include Roche's Cobas HPV assay and Cepheid's GeneXpert Xpert assay for tuberculosis. Adoption of technologies such as FISH and ELISA is also increasing, enhancing diagnostic diversity and expanding clinical applications.

The persistent burden of infectious diseases continues to elevate the need for rapid molecular diagnostics. During the COVID-19 pandemic, RT-PCR and sequencing played a crucial role in virus detection, supported by innovations such as Biosciences' Lyo-Ready RT-qPCR mix and Novacyt's RUO coronavirus assay. Interest in liquid biopsy techniques is also rising, driven by breakthroughs like the 2024 blood test developed by researchers at the University of Chicago and Northwestern University, capable of detecting cancer through circulating DNA fragments.

Molecular diagnostic tools are essential for identifying biomarkers linked to chronic diseases at early stages, enabling timely interventions and improved patient outcomes. According to the CDC, an estimated 129 million Americans were living with at least one major chronic condition in 2024, including heart disease, cancer, diabetes, obesity, or hypertension. Furthermore, 42% of the population manages two or more chronic illnesses, while 12% face five or more. These conditions account for roughly 90% of the nation's annual USD 4.1 trillion healthcare expenditure. With chronic disease prevalence steadily rising, the demand for effective diagnostic and management solutions will continue to climb. Growing cases of cancer, cardiovascular, neurological, and genetic disorders are expected to further drive market growth.

External funding for molecular diagnostics research also plays a vital role in accelerating product innovation. In September 2025, South Korea's Seegene Inc., in collaboration with Springer Nature, launched the 2025-2026 "Nature Awards MDx Impact Grants," offering financial support and access to syndromic PCR assays for developing diagnostics targeting antibiotic-resistant urinary tract infections. Likewise, in April 2023, Promega Corporation awarded USD 15,000 to support academic research using qPCR. Continuous updates to molecular diagnostic test menus are essential, given the evolving nature of infectious diseases and increasing antimicrobial resistance. The COVID-19 outbreak-declared a global health emergency by the WHO in January 2020-underscored the importance of rapid advancements in diagnostic technologies.

Global Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global molecular diagnostics market report based on product, test location, technology, application, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Regards
• Others
• Test Location Outlook (Revenue, USD Million; 2021 - 2033)
• Point of care
• Self test or OTC
• Central laboratories
• Technology Outlook (Revenue, USD Million; 2021 - 2033)
• Polymerase chain reaction (PCR)
  • PCR, by Procedure
  • Nucleic Acid Extraction
  • Others
  • PCR, by Type
  • Multiplex PCR
  • Other PCR
  • PCR, by Product
  • Instruments
  • Reagents
  • Others
• In Situ Hybridization (ISH)
  • Instruments
  • Reagents
  • Others
• Isothermal Nucleic Acid Amplification Technology (INAAT)
  • Instruments
  • Reagents
  • Others
• Chips and Microarrays
  • Instruments
  • Reagents
  • Others
• Mass Spectrometry
  • Instruments
  • Reagents
  • Others
• Transcription Mediated Amplification (TMA)
  • Instruments
  • Reagents
  • Others
• Others
  • Instruments
  • Reagents
  • Others
• Application Outlook (Revenue, USD Million; 2021 - 2033)
• Oncology
  • Breast Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Cervical
  • Kidney
  • Liver
  • Blood
  • Lung
  • Other
• Pharmacogenomics
• Infectious disease
  • MRSA
  • Clostridium difficile
  • Vancomycin-resistant enterococci
  • Carbapenem-resistant bacteria testing
  • Flu
  • Respiratory syncytial virus (RSV)
  • Candida
  • Tuberculosis and drug-resistant TB
  • Meningitis
  • Gastro-intestinal panel testing
  • Chlamydia
  • Gonorrhea
  • HIV
  • Hepatitis C
  • Hepatitis B
  • Other Infectious Diseases
• Genetic testing
  • Newborn screening
  • Predictive and presymptomatic testing
  • Others
• Neurological disease
• Cardiovascular disease
• Microbiology
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
  • Portugal
  • Switzerland
  • Belgium
  • Turkey
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Malaysia
  • Indonesia
  • Vietnam
• Latin America
  • Brazil
  • Argentina
  • Colombia
  • Peru
  • Ecuador
  • Chile
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Content

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. End Use
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Molecular Diagnostics Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Introduction of technologically advanced products
    • 3.2.1.2. Increase in demand for point-of-care Testing
    • 3.2.1.3. Growing prevalence of target diseases
    • 3.2.1.4. Increasing external funding for R&D
    • 3.2.1.5. Outbreak of COVID-19
    • 3.2.1.6. Increase in geriatric population
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Presence of ambiguous regulatory framework
    • 3.2.2.2. High prices of molecular diagnostics tests
• 3.3. Molecular Diagnostics Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Molecular Diagnostics Market: Segment Analysis, By Product, 2021 - 2033 (USD Million)

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2025 & 2033
• 4.3. Molecular Diagnostics Market, by Product, 2021 to 2033
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 4.4.1. Instruments
    • 4.4.1.1. Instruments market, 2021 - 2033 (USD Million)
  • 4.4.2. Reagents
    • 4.4.2.1. Reagents market, 2021 - 2033 (USD Million)
  • 4.4.3. Others
    • 4.4.3.1. Others market, 2021 - 2033 (USD Million)

Chapter 5. Molecular Diagnostics Market: Segment Analysis, By Test Location, 2021 - 2033 (USD Million)

• 5.1. Definition and Scope
• 5.2. Test Location Market Share Analysis, 2025 & 2033
• 5.3. Global Molecular Diagnostics Market, by Test Location, 2021 to 2033
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 5.4.1. Point of care
    • 5.4.1.1. Point of care market, 2021 - 2033 (USD Million)
  • 5.4.2. Self test or OTC
    • 5.4.2.1. Self test or OTC market, 2021 - 2033 (USD Million)
  • 5.4.3. Central laboratories
    • 5.4.3.1. Central laboratories market, 2021 - 2033 (USD Million)

Chapter 6. Molecular Diagnostics Market: Segment Analysis, By Technology, 2021 - 2033 (USD Million)

• 6.1. Definition and Scope
• 6.2. Technology Market Share Analysis, 2025 & 2033
• 6.3. Global Molecular Diagnostics Market, by Technology, 2021 to 2033
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 6.4.1. PCR
    • 6.4.1.1. PCR market, 2021 - 2033 (USD Million)
    • 6.4.1.2. By procedure
      • 6.4.1.2.1. Nucleic acid extraction
        • 6.4.1.2.1.1. Nucleic acid extraction market, 2021 - 2033 (USD Million)
      • 6.4.1.2.2. Others
        • 6.4.1.2.2.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.1.3. By type
      • 6.4.1.3.1. Multiplex
        • 6.4.1.3.1.1. Multiplex market, 2021 - 2033 (USD Million)
      • 6.4.1.3.2. Others
        • 6.4.1.3.2.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.1.4. By product
      • 6.4.1.4.1. Instruments
        • 6.4.1.4.1.1. Instruments market, 2021 - 2033 (USD Million)
      • 6.4.1.4.2. Reagents
        • 6.4.1.4.2.1. Reagents market, 2021 - 2033 (USD Million)
      • 6.4.1.4.3. Others
        • 6.4.1.4.3.1. Others market, 2021 - 2033 (USD Million)
  • 6.4.2. ISH
    • 6.4.2.1. ISH market, 2021 - 2033 (USD Million)
    • 6.4.2.2. Instruments
      • 6.4.2.2.1. Instruments market, 2021 - 2033 (USD Million)
    • 6.4.2.3. Reagents
      • 6.4.2.3.1. Reagents market, 2021 - 2033 (USD Million)
    • 6.4.2.4. Others
      • 6.4.2.4.1. Others market, 2021 - 2033 (USD Million)
  • 6.4.3. INAAT
    • 6.4.3.1. INAAT market, 2021 - 2033 (USD Million)
    • 6.4.3.2. Instruments
      • 6.4.3.2.1. Instruments market, 2021 - 2033 (USD Million)
    • 6.4.3.3. Reagents
      • 6.4.3.3.1. Reagents market, 2021 - 2033 (USD Million)
    • 6.4.3.4. Others
      • 6.4.3.4.1. Others market, 2021 - 2033 (USD Million)
  • 6.4.4. Chips and microarrays
    • 6.4.4.1. Chips and microarrays market, 2021 - 2033 (USD Million)
    • 6.4.4.2. Instruments
      • 6.4.4.2.1. Instruments market, 2021 - 2033 (USD Million)
    • 6.4.4.3. Reagents
      • 6.4.4.3.1. Reagents market, 2021 - 2033 (USD Million)
    • 6.4.4.4. Others
      • 6.4.4.4.1. Others market, 2021 - 2033 (USD Million)
  • 6.4.5. Mass spectrometry
    • 6.4.5.1. Mass spectrometry market, 2021 - 2033 (USD Million)
    • 6.4.5.2. Instruments
      • 6.4.5.2.1. Instruments market, 2021 - 2033 (USD Million)
    • 6.4.5.3. Reagents
      • 6.4.5.3.1. Reagents market, 2021 - 2033 (USD Million)
    • 6.4.5.4. Others
      • 6.4.5.4.1. Others market, 2021 - 2033 (USD Million)
  • 6.4.6. Sequencing
    • 6.4.6.1. Sequencing market, 2021 - 2033 (USD Million)
    • 6.4.6.2. Instruments
      • 6.4.6.2.1. Instruments market, 2021 - 2033 (USD Million)
    • 6.4.6.3. Reagents
      • 6.4.6.3.1. Reagents market, 2021 - 2033 (USD Million)
    • 6.4.6.4. Others
      • 6.4.6.4.1. Others market, 2021 - 2033 (USD Million)
  • 6.4.7. TMA
    • 6.4.7.1. TMA market, 2021 - 2033 (USD Million)
    • 6.4.7.2. Instruments
      • 6.4.7.2.1. Instruments market, 2021 - 2033 (USD Million)
    • 6.4.7.3. Reagents
      • 6.4.7.3.1. Reagents market, 2021 - 2033 (USD Million)
    • 6.4.7.4. Others
      • 6.4.7.4.1. Others market, 2021 - 2033 (USD Million)
  • 6.4.8. Others
    • 6.4.8.1. Others market, 2021 - 2033 (USD Million)
    • 6.4.8.2. Instruments
      • 6.4.8.2.1. Instruments market, 2021 - 2033 (USD Million)
    • 6.4.8.3. Reagents
      • 6.4.8.3.1. Reagents market, 2021 - 2033 (USD Million)
    • 6.4.8.4. Others
      • 6.4.8.4.1. Others market, 2021 - 2033 (USD Million)

Chapter 7. Molecular Diagnostics Market: Segment Analysis, By Application, 2021 - 2033 (USD Million)

• 7.1. Definition and Scope
• 7.2. Application Market Share Analysis, 2025 & 2033
• 7.3. Global Molecular Diagnostics Market, by Application,2021 to 2033
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033
  • 7.4.1. Oncology
    • 7.4.1.1. Oncology market, 2021 - 2033 (USD Million)
    • 7.4.1.2. Breast cancer
      • 7.4.1.2.1. Breast cancer market, 2021 - 2033 (USD Million)
    • 7.4.1.3. Prostate cancer
      • 7.4.1.3.1. Prostate cancer market, 2021 - 2033 (USD Million)
    • 7.4.1.4. Colorectal cancer
      • 7.4.1.4.1. Colorectal cancer market, 2021 - 2033 (USD Million)
    • 7.4.1.5. Cervical
      • 7.4.1.5.1. Cervical market, 2021 - 2033 (USD Million)
    • 7.4.1.6. Kidney
      • 7.4.1.6.1. Kidney market, 2021 - 2033 (USD Million)
    • 7.4.1.7. Liver
      • 7.4.1.7.1. Liver market, 2021 - 2033 (USD Million)
    • 7.4.1.8. Blood
      • 7.4.1.8.1. Blood market, 2021 - 2033 (USD Million)
    • 7.4.1.9. Lung
      • 7.4.1.9.1. Lung market, 2021 - 2033 (USD Million)
    • 7.4.1.10. Other
      • 7.4.1.10.1. Other market, 2021 - 2033 (USD Million)
  • 7.4.2. Pharmacogenomics
    • 7.4.2.1. Pharmacogenomics market, 2021 - 2033 (USD Million)
  • 7.4.3. Infectious disease
    • 7.4.3.1. Infectious disease market, 2021 - 2033 (USD Million)
    • 7.4.3.2. MRSA
      • 7.4.3.2.1. MRSA market, 2021 - 2033 (USD Million)
    • 7.4.3.3. Clostridium difficile
      • 7.4.3.3.1. Clostridium difficile market, 2021 - 2033 (USD Million)
    • 7.4.3.4. Vancomycin-resistant enterococci
      • 7.4.3.4.1. Vancomycin-resistant enterococci market, 2021 - 2033 (USD Million)
    • 7.4.3.5. Carbapenem-resistant bacteria testing
      • 7.4.3.5.1. Carbapenem-resistant bacteria testing market, 2021 - 2033 (USD Million)
    • 7.4.3.6. Flu
      • 7.4.3.6.1. Flu market, 2021 - 2033 (USD Million)
    • 7.4.3.7. Respiratory syncytial virus (RSV)
      • 7.4.3.7.1. Respiratory syncytial virus (RSV) market, 2021 - 2033 (USD Million)
    • 7.4.3.8. Candida
      • 7.4.3.8.1. Candida market, 2021 - 2033 (USD Million)
    • 7.4.3.9. Tuberculosis and drug-resistant TB
      • 7.4.3.9.1. Tuberculosis and drug-resistant TB market, 2021 - 2033 (USD Million)
    • 7.4.3.10. Meningitis
      • 7.4.3.10.1. Meningitis market, 2021 - 2033 (USD Million)
    • 7.4.3.11. Gastro-intestinal panel testing
      • 7.4.3.11.1. Gastro-intestinal panel testing market, 2021 - 2033 (USD Million)
    • 7.4.3.12. Chlamydia
      • 7.4.3.12.1. Chlamydia market, 2021 - 2033 (USD Million)
    • 7.4.3.13. Gonorrhea
      • 7.4.3.13.1. Gonorrhea market, 2021 - 2033 (USD Million)
    • 7.4.3.14. HIV
      • 7.4.3.14.1. HIV market, 2021 - 2033 (USD Million)
    • 7.4.3.15. Hepatitis C
      • 7.4.3.15.1. Hepatitis C market, 2021 - 2033 (USD Million)
    • 7.4.3.16. Hepatitis B
      • 7.4.3.16.1. Hepatitis B market, 2021 - 2033 (USD Million)
    • 7.4.3.17. Other infectious diseases
      • 7.4.3.17.1. Other infectious diseases market, 2021 - 2033 (USD Million)
  • 7.4.4. Genetic testing
    • 7.4.4.1. Genetic testing market, 2021 - 2033 (USD Million)
    • 7.4.4.2. Newborn screening
      • 7.4.4.2.1. Newborn screening market, 2021 - 2033 (USD Million)
    • 7.4.4.3. Predictive and presymptomatic testing
      • 7.4.4.3.1. Predictive and presymptomatic testing market, 2021 - 2033 (USD Million)
    • 7.4.4.4. Others
      • 7.4.4.4.1. Others market, 2021 - 2033 (USD Million)
  • 7.4.5. Neurological disease
    • 7.4.5.1. Neurological disease market, 2021 - 2033 (USD Million)
  • 7.4.6. Cardiovascular disease
    • 7.4.6.1. Cardiovascular disease market, 2021 - 2033 (USD Million)
  • 7.4.7. Microbiology
    • 7.4.7.1. Microbiology market, 2021 - 2033 (USD Million)
  • 7.4.8. Others
    • 7.4.8.1. Others market, 2021 - 2033 (USD Million)

Chapter 8. Molecular Diagnostics Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.4. Spain
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.5. Italy
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.6. Belgium
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Belgium market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.7. Switzerland
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Switzerland market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.8. Netherlands
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Netherlands market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.9. Portugal
    • 8.4.9.1. Key country dynamics
    • 8.4.9.2. Regulatory framework/ reimbursement structure
    • 8.4.9.3. Competitive scenario
    • 8.4.9.4. Portugal market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.10. Denmark
    • 8.4.10.1. Key country dynamics
    • 8.4.10.2. Regulatory framework/ reimbursement structure
    • 8.4.10.3. Competitive scenario
    • 8.4.10.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.11. Sweden
    • 8.4.11.1. Key country dynamics
    • 8.4.11.2. Regulatory framework/ reimbursement structure
    • 8.4.11.3. Competitive scenario
    • 8.4.11.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.12. Turkey
    • 8.4.12.1. Key country dynamics
    • 8.4.12.2. Regulatory framework/ reimbursement structure
    • 8.4.12.3. Competitive scenario
    • 8.4.12.4. Turkey market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.4.13. Norway
    • 8.4.13.1. Key country dynamics
    • 8.4.13.2. Regulatory framework/ reimbursement structure
    • 8.4.13.3. Competitive scenario
    • 8.4.13.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. China
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.2. Japan
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.5. Thailand
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
    • 8.5.5.5. Key country dynamics
    • 8.5.5.6. Regulatory framework/ reimbursement structure
    • 8.5.5.7. Competitive scenario
    • 8.5.5.8. Malaysia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.6. Vietnam
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Vietnam market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.7. Indonesia
    • 8.5.7.1. Key country dynamics
    • 8.5.7.2. Regulatory framework/ reimbursement structure
    • 8.5.7.3. Competitive scenario
    • 8.5.7.4. Indonesia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.5.8. South Korea
    • 8.5.8.1. Key country dynamics
    • 8.5.8.2. Regulatory framework/ reimbursement structure
    • 8.5.8.3. Competitive scenario
    • 8.5.8.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.2. Colombia
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Colombia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.3. Chile
    • 8.6.3.1. Key country dynamics
    • 8.6.3.2. Regulatory framework/ reimbursement structure
    • 8.6.3.3. Competitive scenario
    • 8.6.3.4. Chile market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.4. Peru
    • 8.6.4.1. Key country dynamics
    • 8.6.4.2. Regulatory framework/ reimbursement structure
    • 8.6.4.3. Competitive scenario
    • 8.6.4.4. Peru market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.5. Argentina
    • 8.6.5.1. Key country dynamics
    • 8.6.5.2. Regulatory framework/ reimbursement structure
    • 8.6.5.3. Competitive scenario
    • 8.6.5.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.6.6. Ecuador
    • 8.6.6.1. Key country dynamics
    • 8.6.6.2. Regulatory framework/ reimbursement structure
    • 8.6.6.3. Competitive scenario
    • 8.6.6.4. Ecuador market estimates and forecasts 2021 to 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2025
• 9.4. Key Company Profiles
  • 9.4.1. BD
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. BIOMERIEUX
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Bio-Rad Laboratories, Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Abbott
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Agilent Technologies, Inc.
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Danaher
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Hologic Inc. (Gen Probe)
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. Illumina, Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Grifols
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives
  • 9.4.10. QIAGEN
    • 9.4.10.1. Company overview
    • 9.4.10.2. Financial performance
    • 9.4.10.3. Product benchmarking
    • 9.4.10.4. Strategic initiatives
  • 9.4.11. F. Hoffmann-La Roche, Ltd.
    • 9.4.11.1. Company overview
    • 9.4.11.2. Financial performance
    • 9.4.11.3. Product benchmarking
    • 9.4.11.4. Strategic initiatives
  • 9.4.12. Siemens Healthineers AG
    • 9.4.12.1. Company overview
    • 9.4.12.2. Financial performance
    • 9.4.12.3. Product benchmarking
    • 9.4.12.4. Strategic initiatives
  • 9.4.13. Sysmex Corporation
    • 9.4.13.1. Company overview
    • 9.4.13.2. Financial performance
    • 9.4.13.3. Product benchmarking
    • 9.4.13.4. Strategic initiatives
  • 9.4.14. Seegene Inc
    • 9.4.14.1. Company overview
    • 9.4.14.2. Financial performance
    • 9.4.14.3. Product benchmarking
    • 9.4.14.4. Strategic initiatives
  • 9.4.15. EliTechGroup
    • 9.4.15.1. Company overview
    • 9.4.15.2. Financial performance
    • 9.4.15.3. Product benchmarking
    • 9.4.15.4. Strategic initiatives
  • 9.4.16. CERTEST BIOTEC
    • 9.4.16.1. Company overview
    • 9.4.16.2. Financial performance
    • 9.4.16.3. Product benchmarking
    • 9.4.16.4. Strategic initiativesa